Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A known ✓ | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | NMT1 | P30419 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL1250309 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EKMT2ASMN1; SMN2MAPK1 | |
| Oxalic Acid SCHEMBL1252610 | 0.86 | ALDH1A1 (0.46) | ALDH1A1KDM4EKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL30837586 | 0.84 | CA1 (0.43) | ALDH1A1KDM4EKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL1250322 | 0.84 | CA1 (0.43) | ALDH1A1KDM4EKMT2ASMN1; SMN2MAPK1 | |
| Succinic Acid SCHEMBL1251838 | 0.81 | KDM4E (0.46) | ALDH1A1KDM4EKMT2ASMN1; SMN2MAPK1 | |
| Cadaverine Tartrate SCHEMBL1251771 | 0.80 | MAPK1 (0.41) | ALDH1A1KDM4ESMN1; SMN2MAPK1CYP1A2 | |
| SCHEMBL9227605 | 0.69 | ALDH1A1 (0.55) | ALDH1A1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL9227599 | 0.69 | ALDH1A1 (0.55) | ALDH1A1KMT2ASMN1; SMN2CYP1A2CYP2C9 | |
| SCHEMBL1250311 | 0.69 | MAPK1 (0.37) | ALDH1A1KDM4EKMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL19974183 | 0.69 | ALDH1A1 (0.59) | ALDH1A1KDM4EKMT2ASMN1; SMN2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110045065-A1 | SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | MARVEL LIFE SCIENCES LTD. (GB) | 2011-02-24 | — | — | US | disclosed |
| EP-2252265-A2 | INJECTABLE PREPARATIONS AND A PROCESS OF PREPARATION THEREOF | Marvel Lifesciences Limited (GB) | 2010-11-24 | — | — | EP | disclosed |
| WO-2009116077-A2 | INJECTABLE PREPARATIONS AND A PROCESS OF PREPARATION THEREOF | M.J.BIOPHARM PVT. LTD. (IN) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110045065-A1 | SUBSTANCE HAVING ANTIOXIDANT, GEROPROTECTIVE AND ANTI-ISCHEMIC ACTIVITY AND METHOD FOR THE PREPARATION THEREOF | GPX4, PGC, GSR | KMT2A 4122/4885MEN1 4567/4885ALDH1A1 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.